The interim analysis, announced Tuesday, marks the most significant clinical milestone yet for an individualized mRNA cancer vaccine and sent Moderna shares soaring as much as 160 percent in morning trading. Merck shares rose roughly 12 percent. Analysts at Barclays estimated the therapy could generate about $3 billion in melanoma sales by 2035 if it reaches the market.
What the Trial Found
The vaccine, given in combination with Merck’s blockbuster immunotherapy Keytruda, was tested in patients with high-risk melanoma who had already undergone surgical removal of their tumors. The interim analysis showed the treatment met pre-specified goals for both recurrence-free survival and distant metastasis-free survival — meaning it helped keep cancer from returning locally and from spreading to other parts of the body.
Full detailed data from the interim analysis has not yet been released, and researchers caution that the findings will need to hold up in final analysis and peer review. Still, meeting both endpoints at the interim stage is a stronger signal than many oncologists expected at this stage of development.
How the mRNA Melanoma Vaccine Works
The therapy is built on the same messenger RNA platform Moderna used for its COVID-19 vaccine, but it is tailored to each patient. After a tumor is surgically removed, scientists sequence the cancer’s DNA and identify mutations unique to that tumor. They then design a personalized mRNA vaccine that instructs the patient’s immune system to recognize and attack cells carrying those specific mutations.
This individualized approach has long been considered a promising frontier in cancer immunotherapy, but producing a custom vaccine for each patient within a practical timeframe has been a major logistical hurdle. Moderna’s manufacturing scale-up during the pandemic gave the company infrastructure that could make personalized mRNA production commercially viable.
Market and Competitive Context
Barclays’ $3 billion sales estimate reflects melanoma alone and assumes the therapy secures regulatory approval. If the platform is later validated in other solid tumors — trials in lung cancer and other indications are already planned or underway — the commercial ceiling could be considerably higher.
Merck’s involvement is strategically significant. Keytruda, which generated over $25 billion in 2025 revenue, is approaching patent expiration later this decade. A successful combination therapy would extend Merck’s oncology franchise and protect revenue that would otherwise erode to biosimilar competition. For Moderna, a cancer vaccine approval would diversify the company beyond its reliance on respiratory virus vaccines, a business that has faced uneven demand.
What Happens Next
The companies are expected to present detailed efficacy and safety data at an upcoming medical conference, where oncologists will scrutinize the magnitude of benefit, the durability of the response, and the side-effect profile of the combination. Final analysis of the trial will determine whether the interim findings hold.
Regulatory submission to the U.S. Food and Drug Administration could follow if the data remains strong, though a precise timeline has not been disclosed. Investors and clinicians will also watch for signals on manufacturing turnaround time — how quickly a personalized vaccine can be produced after surgery — because that will determine real-world feasibility outside a trial setting. Expansion into additional cancer types, including non-small cell lung cancer, remains the longer-term catalyst to monitor.
— Aisha Mensah, health desk, AXO News